Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that Dr David Ginsburg and Ms Anne Minto OBE, have been appointed to the Shire Board of Directors with immediate effect.
Dr Ginsburg, MD is currently Professor of Internal Medicine & Human Genetics at the Life Sciences Institute, University of Michigan; an Investigator at the Howard Hughes Medical Institute and the Warner-Lambert/Parke-Davis Professor of Medicine.
Dr Ginsburg qualified at Yale University and has a very distinguished background that includes many research achievements, fellowships, awards and published papers. These have included a research post at Harvard Medical School and numerous senior professorial positions across a broad spectrum of medical specializms at the University of Michigan. Dr Ginsburg has also been appointed to Shire’s Science & Technology Committee.
Anne Minto is Group Director Human Resources at Centrica plc, a FTSE 30 integrated energy company operating in the UK and US. Ms Minto qualified as a lawyer at Aberdeen University and has an impressive business career that includes senior roles at Shell UK and Smiths Group plc and the position of deputy director-general of the Engineering Employers’ Federation.
Ms Minto is a Fellow of both the Chartered Institute of Personnel & Development and the London City and Guilds and a Member of Law Society of Scotland. Anne Minto has also been appointed to Shire’s Remuneration Committee and she will assume the Chair of that Committee on the retirement of Kate Nealon from the Shire Board at the end of Ms Nealon’s term of office at the end of July.
Shire Chairman, Matthew Emmens commented: “I am very pleased that we have attracted two highly qualified and experienced Directors to our Board. David’s medical background and areas of specializm and Anne’s legal, commercial and remuneration experience will be welcome additions to our strong team. I’d like to thank Kate Nealon for her four years of service to Shire’s Board and for her contributions to the Remuneration Committee.”
There is no further information that is required to be disclosed under 9.6.13R of the United Kingdom listing rules.
For further information please contact:
Cléa Rosenfeld (Rest of the World) +44 1256 894 160
Eric Rojas (North America) +1 781 482 0999
Jessica Mann (Rest of the World) +44 1256 894 280
Matthew Cabrey (North America, Specialty Pharma) +1 484 595 8248
Notes to editors
Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company’s website: www.shire.com.